Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 24
1985 55
1986 65
1987 79
1988 104
1989 121
1990 101
1991 122
1992 109
1993 105
1994 112
1995 127
1996 140
1997 128
1998 137
1999 158
2000 115
2001 131
2002 134
2003 128
2004 193
2005 155
2006 170
2007 182
2008 216
2009 222
2010 240
2011 276
2012 305
2013 347
2014 355
2015 348
2016 376
2017 406
2018 382
2019 438
2020 419
Text availability
Article attribute
Article type
Publication date

Search Results

6,734 results
Results by year
Filters applied: . Clear all
Page 1
CA 19-9: Biochemical and Clinical Aspects.
Scarà S, Bottoni P, Scatena R. Scarà S, et al. Adv Exp Med Biol. 2015;867:247-60. doi: 10.1007/978-94-017-7215-0_15. Adv Exp Med Biol. 2015. PMID: 26530370 Review.
CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis a antigen) is the most commonly used and best validated serum tumor marker for pancreatic cancer diagnosis in symptomatic patients
CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lew
New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X. Luo G, et al. Pancreatology. 2018 Dec;18(8):971-976. doi: 10.1016/j.pan.2018.08.003. Epub 2018 Aug 9. Pancreatology. 2018. PMID: 30131287
BACKGROUND: Carbohydrate antigen 19-9 (CA19-9) is the best-validated biomarker for pancreatic cancer. The National Comprehensive Cancer Network (NCCN) guideline asserts that "CA19-9 will be undetectable in Lewis antigen-nega …
BACKGROUND: Carbohydrate antigen 19-9 (CA19-9) is the best-validated biomarker for pancreatic cancer. The …
Predictive Value of Preoperative Serum CA19-9 on Margin Status.
Mosquera C, Johnson HM, Mitsakos AT, Neill NE, Bellamy N, Irish W, Zervos EE, Laks S. Mosquera C, et al. Am Surg. 2019 Sep 1;85(9):965-972. Am Surg. 2019. PMID: 31638508
Serum carbohydrate antigen (CA19-9) is known to correlate with stage, resectability, and prognosis of pancreatic cancer. The goal of pancreaticoduodenectomy is to achieve an R0 resection because worse outcomes are reported in the presence of positive margins. …
Serum carbohydrate antigen (CA19-9) is known to correlate with stage, resectability, and prognosis of pancreatic cancer …
[CA19-9].
Odagiri E. Odagiri E. Nihon Rinsho. 2005 Aug;63 Suppl 8:642-4. Nihon Rinsho. 2005. PMID: 16149600 Review. Japanese. No abstract available.
[CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?].
Juntermanns B, Kaiser GM, Itani Gutierrez S, Heuer M, Buechter M, Kahraman A, Reis H, Kasper S, Paul A, Fingas CD. Juntermanns B, et al. Chirurg. 2018 Jun;89(6):466-471. doi: 10.1007/s00104-018-0636-z. Chirurg. 2018. PMID: 29644426 German.
The role of CA19-9 in terms of patient prognosis is still under debate in the literature. OBJECTIVE: The aim of the present study was to investigate the prognostic value of preoperatively assessed CA19-9 levels in patients with intrahepatic cholangioca …
The role of CA19-9 in terms of patient prognosis is still under debate in the literature. OBJECTIVE: The aim of the present st …
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Luo G, et al. Pancreatology. 2016 Nov-Dec;16(6):1057-1062. doi: 10.1016/j.pan.2016.09.013. Epub 2016 Sep 23. Pancreatology. 2016. PMID: 27692554
BACKGROUND: Carbohydrate antigen 19-9 (CA19-9) is currently the most widely used biomarker for pancreatic cancer. It is well-known that Lewis and Secretor status can affect CA19-9 biosynthesis. ...RESULTS: The Lewis (-), Mixed, and …
BACKGROUND: Carbohydrate antigen 19-9 (CA19-9) is currently the most widely used biomarker for pancreatic …
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts.
Laurent L, Sefrioui D, Bignon AL, Parzy A, Sidali S, Hassine M, Gangloff A, Galais MP, Bouhier-Leporrier K, Michel P, Di Fiore F. Laurent L, et al. HPB (Oxford). 2019 May;21(5):582-588. doi: 10.1016/j.hpb.2018.09.006. Epub 2018 Nov 20. HPB (Oxford). 2019. PMID: 30466797
BACKGROUND: Although carbohydrate antigen 19.9 (CA19.9) is widely used in pancreatic adenocarcinoma (PA), no consensual cut-off value of CA19.9 decrease has been established for treatment monitoring. ...A >15% CA19.9
BACKGROUND: Although carbohydrate antigen 19.9 (CA19.9) is widely used in pancreatic adenocarcinoma (PA), …
Dilemma of elevated CA 19-9 in biliary pathology.
Tsen A, Barbara M, Rosenkranz L. Tsen A, et al. Pancreatology. 2018 Dec;18(8):862-867. doi: 10.1016/j.pan.2018.09.004. Epub 2018 Sep 18. Pancreatology. 2018. PMID: 30249386 Review.
Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker which has been extensively evaluated and widely utilized primarily in diagnosing and prognosticating pancreaticobiliary malignancies. ...These studies have demonstrated that many facto …
Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker which has been extensively evaluated and wid …
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Noguchi K, Suzuki T, Nakamura T, Sato T, Ishigaki K, Hakuta R, Takeda T, Uchino R, Mizuno S, Kogure H, Tada M, Koike K. Takahara N, et al. Cancer Chemother Pharmacol. 2017 Dec;80(6):1105-1112. doi: 10.1007/s00280-017-3456-9. Epub 2017 Oct 16. Cancer Chemother Pharmacol. 2017. PMID: 29038848
PURPOSE: The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated. ...Multivariate analyses showed that CA19-9 response was prognostic both …
PURPOSE: The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (B …
Clinicopathological features of CA19-9-producing gastric cancer.
Yajima H, Omura N, Matai K, Mitsumori N, Yoshida K, Yanaga K. Yajima H, et al. Hepatogastroenterology. 2014 Jan-Feb;61(129):221-5. Hepatogastroenterology. 2014. PMID: 24895825
Patients in whom the CA19-9 level was the cut-off level or higher were defined as having CA19-9-producing gastric cancer (Group A), and their clinicopathological features were compared with those of patients showing CA19-9 levels less tha …
Patients in whom the CA19-9 level was the cut-off level or higher were defined as having CA19-9-producing gastri …
6,734 results
Jump to page
Feedback